696 related articles for article (PubMed ID: 31126191)
1. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
[TBL] [Abstract][Full Text] [Related]
2. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
3. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
[TBL] [Abstract][Full Text] [Related]
4. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
Zhao H; Wang H; Kong F; Xu W; Wang T; Xiao F; Wang L; Huang D; Seth P; Yang Y; Wang H
Hum Gene Ther; 2019 Feb; 30(2):197-210. PubMed ID: 30032645
[TBL] [Abstract][Full Text] [Related]
6. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
[TBL] [Abstract][Full Text] [Related]
7. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
[TBL] [Abstract][Full Text] [Related]
8. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.
Dai S; Lv Y; Xu W; Yang Y; Liu C; Dong X; Zhang H; Prabhakar BS; Maker AV; Seth P; Wang H
Cancer Gene Ther; 2020 Dec; 27(12):923-933. PubMed ID: 32307442
[TBL] [Abstract][Full Text] [Related]
10. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
Seth P; Wang ZG; Pister A; Zafar MB; Kim S; Guise T; Wakefield L
Hum Gene Ther; 2006 Nov; 17(11):1152-60. PubMed ID: 17032151
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model.
Shin SC; Vickman RE; Filimon B; Yang Y; Hu Z; Mangold KA; Prabhakar BS; Schreiber H; Xu W
Cancer Gene Ther; 2024 Apr; 31(4):574-585. PubMed ID: 38267626
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
Hu Z; Zhang Z; Guise T; Seth P
Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
17. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
[TBL] [Abstract][Full Text] [Related]
18. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
20. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.
Dias JD; Hemminki O; Diaconu I; Hirvinen M; Bonetti A; Guse K; Escutenaire S; Kanerva A; Pesonen S; Löskog A; Cerullo V; Hemminki A
Gene Ther; 2012 Oct; 19(10):988-98. PubMed ID: 22071969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
